BioSpace News Archive

Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, and KDx Diagnostics, Inc., a leading developer of bladder cancer tests, today announced that KDx has licensed Acupath to incorporate its URO17™ immunocytochemistry assay test into its enhanced bladder cancer detection program.

The Simón Bolívar Foundation, the 501(c)(3) non-profit, private foundation of CITGO Petroleum Corporation, held an educational and networking event last night for the Houston community regarding the public health situation in Venezuela

Today, OCHIN received three years of federal funding totaling $8.1 million to support nearly 100 health centers across the country

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, August 9, 2019 at 8:00 a.m. ET to discuss the company’s second quarter 2019 financial and operational results.

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 30, 2019, after the close of the U.S. financial markets.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2019, after the market close on Thursday, August 1, 2019.

Pulse Biosciences, Inc., a novel bioelectric medicine company bringing to market its proprietary CellFX™ System announced that the Company will report second quarter 2019 operational highlights and financial results on Thursday, August 8, 2019.

DURECT Corporation announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019.

The Oklahoma Proton Center was named a Top Cancer Center in Oklahoma by Oklahoma Magazine in their annual Best of the Best edition.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 9,125 shares of Puma common stock to two new non-executive employees.